Together, these studies highlight the complex interplay between CKD, neuroinflammation, and gut-derived signals, providing strong evidence that the gut microbiota and its metabolites play a significant role in promoting neuroinflammatory processes in CKD, which in turn contribute to cognitive decline and neurodegenerative changes
On top of this, gut conditions like small intestinal bacterial overgrowth (SIBO), which is more common in women during midlife, can reduce DAO activity further
Cagrilintide vs AOD 9604 Mechanism: Cagrilintide: Amylin receptor agonist (appetite/satiety) AOD 9604: HGH fragment (fat metabolism) Completely different Weight loss: Cagrilintide: 10-12% body weight AOD 9604: 5-8% body weight (less robust data) Cagrilintide superior Clinical evidence: Cagrilintide: Extensive Phase 2/3 trials AOD 9604: Limited clinical data Cagrilintide better studied Side effects: Cagrilintide: GI effects common AOD 9604: Minimal side effects AOD 9604 better tolerated Combination potential: Could theoretically combine (different mechanisms) No clinical data on combination Cagrilintide + semaglutide better established Verdict: Cagrilintide more powerful, better evidence
Warnings: If pregnant, nursing, or taking prescription drugs, consult a healthcare professional before use
#GlowWithTheFaceClinic
